Search

everythinglearnresearchcommunity

for

Search:↓

A 78-year-old man regrew hair after suffering burns, suggesting that injury-induced healing processes might trigger hair growth. Microneedling and other treatments like minoxidil and finasteride are discussed as potential methods to stimulate similar regrowth.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

The user stopped using minoxidil 5 weeks ago due to facial swelling, which initially subsided but then returned. Despite a healthy lifestyle and normal test results, the user is concerned about the persistent bloating.

Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The conversation discusses using high molecular weight hyaluronic acid after microneedling to form a protective barrier, though it's considered expensive and offers marginal improvement. Users share experiences with different microneedling tools like derma rollers, dermastamps, and Dr. Pen, with some opting not to use any products on the scalp.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

The conversation is about seeking hairline regrowth results using RU58841, dermarolling, and Nizoral. The user cannot tolerate finasteride and finds minoxidil ineffective.

The conversation is about finding affordable RU58841 for hair loss treatment. Suggestions include buying it in powder form and making a solution at home, with Amazon as a potential source.

The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.

The conversation discusses making a RU58841 solution for hair loss prevention and includes personal experiences with using RU58841 and minoxidil for hair regrowth, with a mention of monitoring health effects.

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.